Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGN-259 in Dry Eye Syndrome (ARISE-2)
NCT02974907Phase 3Completed
- Sponsor
- ReGenTree
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing RGN-259 with Placebo (2 arms). Primary endpoints: Change in Ocular Discomfort at 29 days and Change in Fluorescein Staining at 29 days. Started Nov 2016; status: completed.
02
Drugs
timbetasin
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02974907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974907.